Your browser doesn't support javascript.
loading
Phototherapy Restores Deficient Type I IFN Production and Enhances Antitumor Responses in Mycosis Fungoides.
Yu, Zizi; Vieyra-Garcia, Pablo; Benezeder, Theresa; Crouch, Jack D; Kim, Ira R; O'Malley, John T; Devlin, Phillip M; Gehad, Ahmed; Zhan, Qian; Gudjonsson, Johann E; Sarkar, Mrinal K; Kahlenberg, J Michelle; Gerard, Nega; Teague, Jessica E; Kupper, Thomas S; LeBoeuf, Nicole R; Larocca, Cecilia; Tawa, Marianne; Pomahac, Bohdan; Talbot, Simon G; Orgill, Dennis P; Wolf, Peter; Clark, Rachael A.
Afiliação
  • Yu Z; Department of Dermatology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
  • Vieyra-Garcia P; Research Unit for Photodermatology, Department of Dermatology and Venereology, Medical University of Graz, Graz, Austria.
  • Benezeder T; Research Unit for Photodermatology, Department of Dermatology and Venereology, Medical University of Graz, Graz, Austria.
  • Crouch JD; Department of Dermatology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
  • Kim IR; Department of Dermatology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
  • O'Malley JT; Department of Dermatology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
  • Devlin PM; Department of Radiation Oncology, Dana-Farber Cancer Institute/Brigham and Women's Cancer Center, Harvard Medical School, Boston, Massachusetts, USA.
  • Gehad A; Department of Dermatology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
  • Zhan Q; Department of Dermatology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
  • Gudjonsson JE; Department of Dermatology, University of Michigan, Ann Arbor, Michigan, USA.
  • Sarkar MK; Department of Dermatology, University of Michigan, Ann Arbor, Michigan, USA.
  • Kahlenberg JM; Division of Rheumatology, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA.
  • Gerard N; Department of Dermatology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
  • Teague JE; Department of Dermatology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
  • Kupper TS; Department of Dermatology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA; Center for Cutaneous Oncology, Dana-Farber Cancer Institute/Brigham and Women's Cancer Center, Harvard Medical School, Boston, Massachusetts, USA.
  • LeBoeuf NR; Department of Dermatology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA; Center for Cutaneous Oncology, Dana-Farber Cancer Institute/Brigham and Women's Cancer Center, Harvard Medical School, Boston, Massachusetts, USA.
  • Larocca C; Department of Dermatology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA; Center for Cutaneous Oncology, Dana-Farber Cancer Institute/Brigham and Women's Cancer Center, Harvard Medical School, Boston, Massachusetts, USA.
  • Tawa M; Center for Cutaneous Oncology, Dana-Farber Cancer Institute/Brigham and Women's Cancer Center, Harvard Medical School, Boston, Massachusetts, USA.
  • Pomahac B; Division of Plastic and Reconstructive Surgery, Department of Surgery, Yale School of Medicine, New Haven, Connecticut, USA.
  • Talbot SG; Division of Plastic and Reconstructive Surgery, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
  • Orgill DP; Division of Plastic and Reconstructive Surgery, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
  • Wolf P; Research Unit for Photodermatology, Department of Dermatology and Venereology, Medical University of Graz, Graz, Austria. Electronic address: peter.wolf@medunigraz.at.
  • Clark RA; Department of Dermatology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA. Electronic address: rclark@bwh.harvard.edu.
J Invest Dermatol ; 144(3): 621-632.e1, 2024 Mar.
Article em En | MEDLINE | ID: mdl-37716650
ABSTRACT
Transcriptional profiling demonstrated markedly reduced type I IFN gene expression in untreated mycosis fungoides (MF) skin lesions compared with that in healthy skin. Type I IFN expression in MF correlated with antigen-presenting cell-associated IRF5 before psoralen plus UVA therapy and epithelial ULBP2 after therapy, suggesting an enhancement of epithelial type I IFN. Immunostains confirmed reduced baseline type I IFN production in MF and increased levels after psoralen plus UVA treatment in responding patients. Effective tumor clearance was associated with increased type I IFN expression, enhanced recruitment of CD8+ T cells into skin lesions, and expression of genes associated with antigen-specific T-cell activation. IFNk, a keratinocyte-derived inducer of type I IFNs, was increased by psoralen plus UVA therapy and expression correlated with upregulation of other type I IFNs. In vitro, deletion of keratinocyte IFNk decreased baseline and UVA-induced expression of type I IFN and IFN response genes. In summary, we find a baseline deficit in type I IFN production in MF that is restored by psoralen plus UVA therapy and correlates with enhanced antitumor responses. This may explain why MF generally develops in sun-protected skin and suggests that drugs that increase epithelial type I IFNs, including topical MEK and EGFR inhibitors, may be effective therapies for MF.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Furocumarinas / Neoplasias Cutâneas / Micose Fungoide Limite: Humans Idioma: En Revista: J Invest Dermatol Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Furocumarinas / Neoplasias Cutâneas / Micose Fungoide Limite: Humans Idioma: En Revista: J Invest Dermatol Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Estados Unidos